Radius Health (NASDAQ: RDUS) reported Q1 EPS of ($0.59), $0.09 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $47.92 million versus the consensus estimate of $46.54 million.

“In these challenging and unprecedented times, I am proud of the Radius team’s quick response and key measures to ensure the safety of our employees, while also providing patients and customers with uninterrupted access to TYMLOS and our investigational medicines,” said Jesper Hoeiland, former Chief Executive Officer of Radius. “I am very enthusiastic about the prospects for Radius and look forward to working with Kelly to make this transition as seamless and effective as possible,” added Jesper.

“I look forward to building on the strong momentum established by Jesper with the TYMLOS franchise and guiding the development of the Company and the achievement of its objectives and advancing it to the next level,” said Kelly Martin, President and CEO of Radius Health.

For earnings history and earnings-related data on Radius Health (RDUS) click here.